YOLFTbeta
hVIVO plc

hVIVO plc

HVO · LSE · Healthcare / Diagnostics & Research

5.05GBX-0.15 (-2.88%)

Price History

Full chart

Market Stats

Previous Close5.20
Open5.18
Day Range4.93 – 5.30
52-Week Range4.31 – 11.00
Volume761.16K
Market Cap41.30M
P/E (TTM)0.00
Forward P/E18.32
EPS-0.02
Dividend Yield0.00%
Beta1.69
50-Day Avg6.63
200-Day Avg7.21

About

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation. In addition, the company offers services combined with specialisms in infectious diseases, respiratory, and cardiometabolic therapeutical areas. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; storage solutions; and statistics services, as well as drug development consultancy and services. The company also provides clinical research services, including early-phase trials and human pharmacological studies. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. Yamin Mohammed Khan Ph.D.
  • Employees376
  • Headquarters40 Bank Street, London, United Kingdom, E14 5NR, UK
  • Websitehttps://www.hvivo.com

Leadership

  • Dr. Yamin Mohammed Khan Ph.D.CEO & Director · b. 1969
  • Mr. Stephen Mark PinkertonCFO & Executive Director · b. 1963
  • Mr. Andrew CatchpoleChief Scientific Officer
  • Ms. Teja Marathe-SarvadikarHead of Quality Assurance
  • Dr. Thomas Forst M.D.Chief Medical Officer
  • Mr. Erik GoutHead of CMC
  • Mr. Chris ForsdykeHead of Laboratory Services
  • Dr. Sara ArmaniHead of Medical Affairs
  • Ms. Isabelle AckermannHead of Data Management

Financials

Income Statement

Currency: GBP2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.87M2.19M1.70M3.81M8.47M15.27M15.45M12.55M3.28M20.60M36.86M48.48M56.04M62.73M46.77M
Growth (%)--23.60%-22.30%+123.86%+121.96%+80.29%+1.21%-18.78%-73.83%+527.33%+78.93%+31.50%+15.61%+11.92%-25.43%
Cost of Revenue--------8.06M727.00K963.00K44.47M45.63M53.36M52.90M
Gross Profit2.87M2.19M1.70M3.81M8.47M15.27M15.45M12.55M-4.78M19.88M35.90M4.00M10.41M62.73M-6.12M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%-145.55%96.47%97.39%8.26%18.58%100.00%-13.09%
Operating Expense1.83M3.11M3.21M5.20M8.68M15.74M15.41M14.68M206.80K30.32M35.31M-2.02M312.00K49.87M-5.77M
Operating Income1.04M-919.86K-1.50M-1.38M-210.32K-478.20K46.16K-2.13M-4.99M-10.44M590.00K6.02M10.10M12.86M-349.00K
Operating Margin36.26%-41.94%-88.16%-36.19%-2.48%-3.13%0.30%-17.00%-151.85%-50.68%1.60%12.42%18.03%20.50%-0.75%
EBITDA1.07M-882.21K-1.47M-1.23M520.27K-77.57K-806.07K-3.67M-4.83M-8.55M3.07M2.70M14.02M17.80M4.31M
EBITDA Margin37.31%-40.22%-86.00%-32.17%6.14%-0.51%-5.22%-29.23%-147.04%-41.52%8.33%5.57%25.01%28.38%9.21%
Net Income1.01M-959.14K-1.51M-1.20M11.07K453.48K-1.37M-4.30M-5.59M-10.79M-74.00K-776.00K16.11M10.65M-5.99M
Net Income Margin35.21%-43.73%-88.45%-31.39%0.13%2.97%-8.84%-34.30%-170.21%-52.38%-0.20%-1.60%28.75%16.98%-12.81%
R&D-----------82.00K31.18K-5.77M
R&D as % of Total Revenue-----------0.17%0.06%-12.34%
Interest Expense12.52K23.73K34.33K55.47K32.47K--5.41K350.00K374.00K227.00K133.00K176.00K1.11M1.20M
Interest Expense % of Total Revenue0.44%1.08%2.01%1.45%0.38%--0.04%10.66%1.82%0.62%0.27%0.31%1.77%2.57%

Balance Sheet

Currency: GBP2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.74M3.60M1.99M4.67M11.24M12.54M10.84M7.81M9.08M48.55M42.27M51.38M83.23M88.89M71.81M
Total Liabilities1.64M1.53M1.38M3.26M3.69M3.65M3.07M3.88M6.22M26.25M21.59M31.16M48.90M44.22M33.66M
Total Equity104.35K2.07M603.77K982.83K7.31M8.89M7.77M3.93M2.86M22.30M20.68M20.22M34.33M44.67M38.16M
Cash93.50K2.35M453.03K629.70K2.80M2.90M1.04M989.83K1.04M19.20M15.69M28.44M36.97M44.18M14.30M
Total Debt234.57K531.95K272.15K306.25K64.20K51.14K22.19K1.41M3.14M4.80M3.15M2.30M12.53M12.90M14.79M
Net Debt141.08K-1.82M-180.88K-323.44K-2.74M-2.85M-1.02M418.29K2.10M-14.41M-12.55M-26.14M-24.44M-31.28M490.00K

Cash Flow

Currency: GBP2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow907.41K-686.62K-1.56M-803.14K-1.59M-293.23K-1.17M-996.14K-2.78M4.17M-1.56M15.98M17.24M10.34M-13.40M
Investing Cash Flow-60.10K374.00K-61.13K-306.26K-2.08M-67.34K-898.40K-93.75K416.06K1.18M-739.00K-1.36M-5.18M-660.00K-11.90M
Financing Cash Flow-1.29M2.57M-303.14K1.41M6.03M-46.88K-31.07K1.02M3.26M13.04M-1.20M-1.83M-4.70M-2.40M-4.56M
Capital Expenditure64.28K14.73K25.96K77.35K526.17K0485.60K71.22K23.07K1.09M739.00K1.36M5.18M2.46M1.40M
Free Cash Flow843.13K-701.35K-1.58M-880.48K-2.11M-293.23K-1.66M-1.07M-2.80M3.08M-2.30M14.62M12.06M7.88M-14.80M
Dividends Paid------------3.05M1.36M1.37M
FCF to OCF92.92%102.15%101.67%109.63%133.16%100.00%141.47%107.15%100.83%73.82%147.25%91.48%69.97%76.20%110.42%
Dividend Paid to FCF------------25.32%17.24%-9.27%

Earnings

Report DateMay 26, 2016Sep 28, 2016Mar 31, 2017Sep 12, 2017Jun 6, 2018Sep 10, 2018May 15, 2019Sep 30, 2020Jun 17, 2021Sep 20, 2021Jun 7, 2022Sep 19, 2022Apr 25, 2023May 2, 2025Sep 8, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.00-
EPS Actual0.010.00-0.02-0.01-0.02-0.01-0.05-0.02-0.010.000.000.000.000.010.00
Surprise---------------
Timing------------After-hours-Pre-market

Key Statistics & Ratios

Market Cap41.30M
Enterprise Value46.37M
Trailing P/E0.00
Forward P/E18.32
Price / Sales0.83
Price / Book1.42
EPS-0.02
Book Value0.056
Revenue (TTM)49.66M
Gross Profit (TTM)1.42M
EBITDA-631.00K
Profit Margin-12.07%
Operating Margin-17.76%
Return on Equity-14.47%
Return on Assets-2.52%
Shares Outstanding688.40M
Shares Float564.31M
Beta1.69
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20251×
0.00May 15, 2025
20241×
0.00Apr 18, 2024
20231×
0.00May 4, 2023

Stock Splits

  • Dec 14, 20121:30